Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
personalized mRNA tumor vaccine (Xinxin Zhang)
- Development stage
- Unknown
- Lead developer
- Xinxin Zhang
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
01
Overview
This personalized mRNA tumor vaccine is an investigational biological therapy developed by Xinxin Zhang for the treatment of refractory rhabdomyosarcoma. The vaccine is engineered using messenger RNA technology to encode tumor-specific antigens unique to an individual patient's malignancy. Upon administration, the mRNA is translated into proteins that serve as antigens, stimulating the patient's immune system—specifically T-cells—to recognize and eliminate rhabdomyosarcoma cells. It is currently being evaluated in an early phase 1 exploratory clinical trial (NCT06932861) focusing on safety and feasibility in pediatric and adult patients (aged 6 and older) with no other viable treatment options.
- Other names
- mRNA Tumor Vaccine TherapyPersonalized mRNA Vaccine in Refractory Rhabdomyosarcoma
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on personalized mRNA tumor vaccine (Xinxin Zhang).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on personalized mRNA tumor vaccine (Xinxin Zhang).